The percentages of VISTA and PD-L1 expression on tumor-infiltrating CD4+ and CD8+ T cells and CD68+ macrophages were significantly increased after therapy, suggesting that both checkpoint proteins may contribute to the immunosuppressive tumor microenvironment (TME) and resistance to negative immune checkpoint blockade therapy (8). This evidence concerns the gene CD4 and neoplasm.